Stock Analiz

NEUROONE MEDICAL TECHNOLOGIES Corp NMTC

Medical/Dental Instruments · data as of November 13, 2026

$0.75Market cap $7M
Open the interactive analysis →

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $9M and net income of -$7M, a net margin of -78.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -251%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 2% below the current price.

About NEUROONE MEDICAL TECHNOLOGIES

NEUROONE MEDICAL TECHNOLOGIES is listed in the US and classified in medical/dental instruments. Revenue went from $773 in 2014 to $9M in 2025, growth of about 134.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 151% over three years (dilution for shareholders). It spends 55% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.7
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-105.6%
Shareholder yield0.0%
Intrinsic value vs. price−2%

Growth and quality

Revenue growth (1 yr)163.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2486.0%
ROIC (5-yr avg.)-251.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201720162015
Revenue$9M$9M$3M$2M$171169$178146———$0$0
Net income-$7M-$4M-$12M-$12M-$10M-$10M-$14M-$7M-$5M-$47775-$62863
Free cash flow-$7M-$3M-$11M-$13M-$8M-$9M-$4M-$5M———
EPS (diluted)$-0.36$-0.09$-0.46$-0.65$-0.63$-0.93$-2.52$-1.71$-2.31$-0.03$-0.03
Net margin-78.6%-39.6%-356.7%-607.4%-5841.9%-5584.3%—————
ROIC—-45.5%-867.8%-145.6%-80.5%-116.0%-108.1%————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is NEUROONE MEDICAL TECHNOLOGIES stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 2% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does NEUROONE MEDICAL TECHNOLOGIES pay a dividend?

Not currently.

Is NEUROONE MEDICAL TECHNOLOGIES a good stock to buy?

We do not give buy or sell advice. NEUROONE MEDICAL TECHNOLOGIES scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.